These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 33405294)

  • 1. The role of the microbiome and the NLRP3 inflammasome in the gut and lung.
    Donovan C; Liu G; Shen S; Marshall JE; Kim RY; Alemao CA; Budden KF; Choi JP; Kohonen-Corish M; El-Omar EM; Yang IA; Hansbro PM
    J Leukoc Biol; 2020 Sep; 108(3):925-935. PubMed ID: 33405294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Huang S; Chen Z; Fan B; Chen Y; Zhou L; Jiang B; Long H; Zhong W; Li X; Li Y
    J Neuroimmunol; 2021 May; 354():577543. PubMed ID: 33714750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
    Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
    Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NLRP3 inflammasome mediates DSS-induced intestinal inflammation in Nod2 knockout mice.
    Umiker B; Lee HH; Cope J; Ajami NJ; Laine JP; Fregeau C; Ferguson H; Alves SE; Sciammetta N; Kleinschek M; Salmon M
    Innate Immun; 2019 Feb; 25(2):132-143. PubMed ID: 30774010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
    Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
    Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
    Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
    J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
    Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
    J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review.
    Wu D; Chen Y; Sun Y; Gao Q; Li H; Yang Z; Wang Y; Jiang X; Yu B
    Inflammation; 2020 Feb; 43(1):17-23. PubMed ID: 31646445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammasome Activation in Ankylosing Spondylitis Is Associated With Gut Dysbiosis.
    Guggino G; Mauro D; Rizzo A; Alessandro R; Raimondo S; Bergot AS; Rahman MA; Ellis JJ; Milling S; Lories R; Elewaut D; Brown MA; Thomas R; Ciccia F
    Arthritis Rheumatol; 2021 Jul; 73(7):1189-1199. PubMed ID: 33452867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.
    Coll RC; Hill JR; Day CJ; Zamoshnikova A; Boucher D; Massey NL; Chitty JL; Fraser JA; Jennings MP; Robertson AAB; Schroder K
    Nat Chem Biol; 2019 Jun; 15(6):556-559. PubMed ID: 31086327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
    Sui A; Chen X; Shen J; Demetriades AM; Yao Y; Yao Y; Zhu Y; Shen X; Xie B
    Cell Death Dis; 2020 Oct; 11(10):901. PubMed ID: 33093455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLRP3 inflammasome inhibition attenuates subacute neurotoxicity induced by acrylamide in vitro and in vivo.
    Sui X; Yang J; Zhang G; Yuan X; Li W; Long J; Luo Y; Li Y; Wang Y
    Toxicology; 2020 Feb; 432():152392. PubMed ID: 32014472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.
    Nalbandian A; Khan AA; Srivastava R; Llewellyn KJ; Tan B; Shukr N; Fazli Y; Kimonis VE; BenMohamed L
    Inflammation; 2017 Feb; 40(1):21-41. PubMed ID: 27730320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammasome-Independent Role for NLRP3 in Controlling Innate Antihelminth Immunity and Tissue Repair in the Lung.
    Chenery AL; Alhallaf R; Agha Z; Ajendra J; Parkinson JE; Cooper MM; Chan BHK; Eichenberger RM; Dent LA; Robertson AAB; Kupz A; Brough D; Loukas A; Sutherland TE; Allen JE; Giacomin PR
    J Immunol; 2019 Nov; 203(10):2724-2734. PubMed ID: 31586037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
    Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
    Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRP3 inflammasome activates interleukin-23/interleukin-17 axis during ischaemia-reperfusion injury in cerebral ischaemia in mice.
    Wang H; Zhong D; Chen H; Jin J; Liu Q; Li G
    Life Sci; 2019 Jun; 227():101-113. PubMed ID: 31002919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of NLRP3 inflammasome alleviates cognitive deficits in a mouse model of anti-NMDAR encephalitis induced by active immunization.
    Yang X; Sun A; Kong L; Yang X; Zhao X; Wang S
    Int Immunopharmacol; 2024 Aug; 137():112374. PubMed ID: 38851162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
    Yaw ACK; Chan EWL; Yap JKY; Mai CW
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2219-2229. PubMed ID: 32507974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome.
    Li H; Guan Y; Liang B; Ding P; Hou X; Wei W; Ma Y
    Eur J Pharmacol; 2022 Aug; 928():175091. PubMed ID: 35714692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.